Transorb Self-Gripping Resorbable Mesh (TSB1510 / TSB2020 / TSB3030 / TSB4030)
Sofradim Production · Decision date Oct 16, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-16 for Transorb™ Self-Gripping Resorbable Mesh, submitted by Sofradim Production of Trévoux, France, under 510(k) number K262443. The device is listed under the classification name Mesh, Surgical, Absorbable, Abdominal Hernia, regulation number 878.3300, with primary product code OWT and subsequent codes FTL and OOD. The listed models are TSB1510, TSB2020, TSB3030 and TSB4030.
The application was received 07/16/2026 as a traditional 510(k), reviewed by FDA rather than a third party, and was not a combination product; no predetermined change control plan was authorized. SESE means the submission was cleared as substantially equivalent to a predicate, not granted PMA approval. The public record does not state the predicate device, the indications for use, or the basis for the equivalence determination; those details would sit in the underlying review documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262443
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Sofradim Production
- Product code
- OWT
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mesh, Surgical, Absorbable, Abdominal Hernia.
- Applicant
- Sofradim Production
- Product code
- OWT
- FDA device class
- 2
FDA decision timeline
K262443 received
Application receipt date recorded by FDA.
K262443 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code OWT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Davol, Inc., A Subsidiary of C.R. Bard, Inc. | 510(k) clearance | Sep 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sofradim Production
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Trévoux
Sources and methodology
- Original FDA record: K262443
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records